New research reveals that patients who stop using new weight-loss injections like Wegovy and Mounjaro can put back on shed pounds far faster than those who end conventional lifestyle regimens.
Findings released in a prominent health publication shows that while obese individuals frequently drop about a fifth of their total mass while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"Users purchasing these treatments need to be aware of the potential of fast rebound weight gain when the medication concludes," warns lead investigator Dr. Susan Jebb.
Such speed of regain implies a return to pre-treatment mass in about one and a half years.
Comparing Treatments
The study, which examined 37 of studies involving over 9,000 of patients, contrasted the results of these new drugs with older methods.
Researchers emphasize that people who lose weight through dieting typically have a slower creep back—approximately 0.1 kg a month—after stopping.
The Reason for the Fast Rebound
Nutrition scientists suggest the mechanism of the jabs explains the heightened regain.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Artificially providing the hormone concentrations several times higher than normal may cause the body to produce less of its own natural GLP-1, and could lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication leads to appetite is unsuppressed, making overeating much more probable."
An Ongoing Condition?
Health authorities suggest the jabs for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, due to the significant potential of weight regain, the therapy might need to be long-term.
This opinion is supported by drug manufacturers, who say that the findings "underscore the long-term character of obesity," similar to managing conditions like hypertension.
Patient Experiences
Individuals who have stopped the jabs describe a intense return of appetite.
"It was like a switch that goes on and I was suddenly starving," recalled one woman.
The struggle is compounded if users have not developed lasting lifestyle or habit modifications during therapy.
Widespread Use
Figures indicate that millions of people in the UK have tried these injections in the past year, with demand being substantial.
- Use is higher among women than men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Ultimately, researchers stress that while GLP-1 drugs are powerful tools for shedding pounds, they are not a permanent cure and lasting health benefits hinges on integrated lifestyle support.